These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 34320709)

  • 21. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
    Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
    Hyman DM; Sill MW; Lankes HA; Piekarz R; Shahin MS; Ridgway MR; Backes F; Tenney ME; Mathews CA; Hoffman JS; Aghajanian C; Hensley ML
    Gynecol Oncol; 2017 Jan; 144(1):96-100. PubMed ID: 28094040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
    Akin S; Dizdar O; Karakas Y; Turker A; Kars A
    Curr Probl Cancer; 2018; 42(3):344-349. PubMed ID: 29576383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
    Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
    Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
    Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uterine leiomyosarcoma--a Singapore experience.
    Soh LT; Chew SH; Ang L
    Aust N Z J Obstet Gynaecol; 1999 May; 39(2):246-8. PubMed ID: 10755790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis.
    Leitao MM; Zivanovic O; Chi DS; Hensley ML; O'Cearbhaill R; Soslow RA; Barakat RR
    Gynecol Oncol; 2012 May; 125(2):409-13. PubMed ID: 22366592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
    Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
    Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful clinical approach to the metastatic uterine leiomyosarcoma to the epicardium-a case report.
    Krzelj K; Lekic A; Luksic VR; Milicic D; Ilic I; Simetic L; Dzepina ZS; Gasparovic H; Biocina B; Safradin I
    BMC Cardiovasc Disord; 2024 Jan; 24(1):49. PubMed ID: 38218764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital.
    Dinh TA; Oliva EA; Fuller AF; Lee H; Goodman A
    Gynecol Oncol; 2004 Feb; 92(2):648-52. PubMed ID: 14766261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
    Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
    Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uterine leiomyosarcoma: analysis of treatment failures and survival.
    Gadducci A; Landoni F; Sartori E; Zola P; Maggino T; Lissoni A; Bazzurini L; Arisio R; Romagnolo C; Cristofani R
    Gynecol Oncol; 1996 Jul; 62(1):25-32. PubMed ID: 8690287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10-year experience of a single institute.
    Kodama K; Sonoda K; Kijima M; Yamaguchi S; Yagi H; Yasunaga M; Ohgami T; Onoyama I; Kaneki E; Okugawa K; Yahata H; Ohishi Y; Oda Y; Kato K
    Asia Pac J Clin Oncol; 2020 Apr; 16(2):e63-e67. PubMed ID: 31721462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The treatment of uterine leiomyosarcoma: clinical outcomes of 18 cases and the effectiveness of chemotherapy.
    Matoda M; Takeshima N; Nomura H; Kino M; Omatsu K; Iwase H; Umayahara K; Takizawa K
    Eur J Gynaecol Oncol; 2011; 32(6):647-50. PubMed ID: 22335027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis.
    Bogani G; Fucà G; Maltese G; Ditto A; Martinelli F; Signorelli M; Chiappa V; Scaffa C; Sabatucci I; Lecce F; Raspagliesi F; Lorusso D
    Gynecol Oncol; 2016 Nov; 143(2):443-447. PubMed ID: 27481579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma.
    Leitao MM; Brennan MF; Hensley M; Sonoda Y; Hummer A; Bhaskaran D; Venkatraman E; Alektiar K; Barakat RR
    Gynecol Oncol; 2002 Dec; 87(3):287-94. PubMed ID: 12468327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y; Brahmi SA; Afqir S
    Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of ABO Blood Groups in Patients with Glioblastoma Multiforme.
    Sokmen FC; Karacin C
    J Coll Physicians Surg Pak; 2020 Jul; 30(7):713-716. PubMed ID: 32811600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
    Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of surgery in the multimodal treatment of primary and recurrent leiomyosarcoma of the inferior vena cava.
    Cananzi FC; Mussi C; Bordoni MG; Marrari A; De Sanctis R; Colombo P; Quagliuolo V
    J Surg Oncol; 2016 Jul; 114(1):44-9. PubMed ID: 27062161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.